US Equities Analysis

EW — Edwards Lifesciences

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 31.22%
Profit Margins 17.39%
Return on Equity 10.46%
Return on Assets 8.27%
Free Float 0.57B
Short Int % Utilisation 2.4%

2.2 Growth

Metric Value
Revenue Growth 16.7%
Free Cash Flow 0.9B
EBITDA 24.45 (Ratio)
Enterprise Value 46.54B
EV/Revenue 7.38
EV/EBITDA 24.45

Revenue growth of 16.7% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 20.77%
Risk / Std Dev (Ann.)* 24.63%
1-Year Price Return* 17.05%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $91.60
52-Week Range $72.30 – $96.29
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

2.5 Valuation & Cash Flow

Valuation basis: The operating-company framework starts with reported EBIT, taxes, non-cash charges, capital expenditure and working-capital movement to derive unlevered free cash flow. It is a current-input research view, not an intrinsic-value target price because a sourced forecast and peer-beta workstream are still required.

Valuation input Value
Last market price $90.81
Market capitalisation $52.29B
Enterprise value proxy $48.77B
Revenue $6.07B
EBIT $1.29B
EBITDA $1.45B
Reported free cash flow $1.33B
Unlevered free cash flow $1.12B
FCF yield 2.55%
EV / EBITDA proxy 33.64x
Net debt / EBITDA -2.43x

WACC Workbench

WACC input Value
Risk-free rate 4.72%
Equity risk premium assumption 5.50%
Beta 0.85
Cost of equity 9.38%
Pre-tax cost of debt 2.90%
WACC 9.28%
WACC validation within standard range

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and statement data; retrieval timestamp: 2026-08-17 23:36:29.873974 UTC; latest reported fiscal period: 2025-12-31 00:00:00. WACC uses a live 10-year Treasury proxy when available, a 5.50% ERP assumption, reported beta where available, and an interest-expense / average-debt proxy for cost of debt. This is research and analysis only, not personalized financial advice.

us-equity stock equity ew health-care health-care-equipment nasdaq